Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1969 1
1970 2
1971 1
1972 1
1973 2
1974 3
1975 6
1976 7
1977 3
1978 3
1979 5
1980 9
1981 7
1982 10
1983 8
1984 7
1985 8
1986 17
1987 11
1988 12
1989 10
1990 10
1991 17
1992 20
1993 21
1994 28
1995 26
1996 42
1997 35
1998 30
1999 30
2000 45
2001 49
2002 53
2003 66
2004 53
2005 70
2006 74
2007 77
2008 83
2009 97
2010 99
2011 126
2012 124
2013 155
2014 171
2015 145
2016 148
2017 155
2018 153
2019 141
2020 120
2021 118
2022 95
2023 61
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

2,526 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Esophagus Mucositis or Stomatitis by Functional or Symptomatic Classification, CTCAE"
Page 1
The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies.
Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. Elad S, et al. CA Cancer J Clin. 2022 Jan;72(1):57-77. doi: 10.3322/caac.21704. Epub 2021 Oct 29. CA Cancer J Clin. 2022. PMID: 34714553 Free article. Review.
Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the …
Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, qua …
Recurrent aphthous stomatitis.
Akintoye SO, Greenberg MS. Akintoye SO, et al. Dent Clin North Am. 2014 Apr;58(2):281-97. doi: 10.1016/j.cden.2013.12.002. Epub 2014 Jan 21. Dent Clin North Am. 2014. PMID: 24655523 Free PMC article. Review.
Recurrent aphthous stomatitis (RAS) is the most common ulcerative disease affecting the oral mucosa. ...
Recurrent aphthous stomatitis (RAS) is the most common ulcerative disease affecting the oral mucosa. ...
Oral pathology in inflammatory bowel disease.
Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Muhvić-Urek M, et al. World J Gastroenterol. 2016 Jul 7;22(25):5655-67. doi: 10.3748/wjg.v22.i25.5655. World J Gastroenterol. 2016. PMID: 27433081 Free PMC article. Review.
Specific oral manifestations in patients with CD are as follows: indurate mucosal tags, cobblestoning and mucogingivitis, deep linear ulcerations and lip swelling with vertical fissures. The most common non-specific manifestations, such as aphthous stomatitis and an …
Specific oral manifestations in patients with CD are as follows: indurate mucosal tags, cobblestoning and mucogingivitis, deep linear …
Prevalences of peri-implantitis and peri-implant mucositis: systematic review and meta-analysis.
Lee CT, Huang YW, Zhu L, Weltman R. Lee CT, et al. J Dent. 2017 Jul;62:1-12. doi: 10.1016/j.jdent.2017.04.011. Epub 2017 May 3. J Dent. 2017. PMID: 28478213 Review.
DATA: Forty seven studies were selected and prevalences of peri-implant diseases were analyzed. Since heterogeneity existed in each outcome (I(2)=94.7, 95.7, 95.3, and 99.3 for implant-based and subject-based peri-implantitis and peri-implant mucositis, respectively …
DATA: Forty seven studies were selected and prevalences of peri-implant diseases were analyzed. Since heterogeneity existed in each outcome …
Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis.
Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, Heaivilin N, Zumsteg ZS. Sroussi HY, et al. Cancer Med. 2017 Dec;6(12):2918-2931. doi: 10.1002/cam4.1221. Epub 2017 Oct 25. Cancer Med. 2017. PMID: 29071801 Free PMC article. Review.
The oral morbidities of radiation therapy include but are not limited to an increased susceptibility to dental caries and periodontal disease. They also include profound and often permanent functional and sensory changes involving the oral soft tissue. These changes range …
The oral morbidities of radiation therapy include but are not limited to an increased susceptibility to dental caries and periodontal diseas …
Peri-implant Mucositis.
Froum SJ, González de la Torre E, Rosen PS. Froum SJ, et al. Int J Periodontics Restorative Dent. 2019 Mar/Apr;39(2):e46-e57. doi: 10.11607/prd.3976. Int J Periodontics Restorative Dent. 2019. PMID: 30794253 Review.
Peri-implant mucositis has been defined as a reversible inflammatory reaction in the soft tissues around a functioning implant with no bone loss. This paper reviews the prevalence, etiology, risk indicators, prevention, and treatment of mucositis. Relying on …
Peri-implant mucositis has been defined as a reversible inflammatory reaction in the soft tissues around a functioning implant …
AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. Sharma P, et al. Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. Epub 2019 Nov 12. Gastroenterology. 2020. PMID: 31730766 Review.
BEST PRACTICE ADVICE 2: Both BET and continued surveillance are reasonable options for the management of BE patients with confirmed and persistent low-grade dysplasia. ...BEST PRACTICE ADVICE 15: The approach to recurrent disease is similar to that of the initial th …
BEST PRACTICE ADVICE 2: Both BET and continued surveillance are reasonable options for the management of BE patients with confirmed a …
Barrett esophagus: diagnostic challenges.
Hagen CE, Lauwers GY, Mino-Kenudson M. Hagen CE, et al. Semin Diagn Pathol. 2014 Mar;31(2):100-13. doi: 10.1053/j.semdp.2014.02.005. Epub 2014 Feb 12. Semin Diagn Pathol. 2014. PMID: 24815936 Review.
In this review, we will discuss issues associated with the diagnosis of Barrett esophagus, including the definition of Barrett esophagus and its distinction from carditis with intestinal metaplasia. ...Finally, we will touch upon the evaluation of dysplasia in endos …
In this review, we will discuss issues associated with the diagnosis of Barrett esophagus, including the definition of Barrett eso …
Chemotherapy and dysphagia: the good, the bad, the ugly.
Dewan K. Dewan K. Curr Opin Otolaryngol Head Neck Surg. 2020 Dec;28(6):385-391. doi: 10.1097/MOO.0000000000000672. Curr Opin Otolaryngol Head Neck Surg. 2020. PMID: 33027141 Review.
The most common dysphagia causing toxicity of chemotherapeutic agents is mucositis/stomatitis. The use of cisplatin is correlated with increased incidence of mucositis. Similarly, the addition of melphalan is also associated with worsening mucositis an …
The most common dysphagia causing toxicity of chemotherapeutic agents is mucositis/stomatitis. The use of cisplatin is correla …
Emerging evidence on the pathobiology of mucositis.
Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Al-Dasooqi N, et al. Support Care Cancer. 2013 Nov;21(11):3233-41. doi: 10.1007/s00520-013-1900-x. Epub 2013 Jul 11. Support Care Cancer. 2013. PMID: 23842598 Review.
BACKGROUND: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. …
BACKGROUND: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barri …
2,526 results